Skip to main
IMMP

Immutep Ltd (IMMP) Stock Forecast & Price Target

Immutep Ltd (IMMP) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Immutep Ltd's development of eftilagimod alfa (efti) has demonstrated significant clinical efficacy, particularly in the treatment of non-small cell lung cancer (1L NSCLC), where it has notably increased the overall response rates (ORR) for patients with low tumor proportion score (TPS <1%) by 22.2% over historical treatment rates. The company's strong intellectual property portfolio surrounding efti enhances its potential for combination therapies, particularly with existing PD-(L)1 franchise treatments, paving the way for broader market applications and partnerships. Overall, the combination of promising clinical trial results and robust product development strategies contributes to a positive outlook for Immutep's stock performance.

Bears say

Immutep Ltd faces significant challenges in advancing its lead product candidate, eftilagimod alfa (efti), as the probability of success for its registrational Phase three clinical trial in non-small cell lung cancer has been reduced to just 30% due to underwhelming clinical results. Additionally, there are concerns regarding the efficacy of eftilagimod in comparison to historical data, particularly as results from the INSIGHT-003 trial are expected to be inferior due to a higher number of low TPS patients, which may lead to diminished overall efficacy metrics. Furthermore, LAG-3 antagonists, including Immutep's offerings, have historically delivered mixed results in lung cancer, creating a perceptual headwind that diminishes investor confidence in their potential to change clinical practice.

Immutep Ltd (IMMP) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immutep Ltd (IMMP) Forecast

Analysts have given Immutep Ltd (IMMP) a Hold based on their latest research and market trends.

According to 2 analysts, Immutep Ltd (IMMP) has a Hold consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immutep Ltd (IMMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.